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treatment of 16,035 patients in 2009 (7,150,000 CHF; new service) with 2007
(7,184,000 CHF; old service, adjusted to 16,035 patients) showed slightly reduced
costs (-34,000 CHF; 95%-CI:60,000 to -127,000).CONCLUSIONS:The cost reduction
of 0.5% is a conservative estimate as wages have increased since 2007. The reor-
ganisation has the potential to be a dominant intervention: While quality of service
provision improved, treatment costs slightly decreased against the secular trend of
increase. Data has to be confirmed in follow-up measurements for decision mak-
ers.
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OBJECTIVES: The Stability and Growth Pact approved by the Portuguese Govern-
ment in 2010 limits the expenditure growth in 1% for reimbursed pharmaceuticals
in outpatient sector. The Memorandum of Understanding signed in May 2011 be-
tween the Government and the International Authorities subsequently has in-
creased the requirements to reduce public expenditure. Considering the pricing
and reimbursement changes, this study aims to: 1) analyze public expenditure
trends on medicines, and 2) identify the main factors and impacts. METHODS: We
have analyzed the database sales and prescription data from Portuguese commu-
nity pharmacies, and performed simulations to measure the impact of policy mea-
sures. The statistical analysis of monthly data by product was performed with SAS.
RESULTS: The NHS expenditure in outpatient medicines has increased 5.6% in
2010. The legislation approved in June 2009, that established generics reimburse-
ment at 100% for some pensioners (withdrawn in June 2010), was responsible for
more 26.8 million euros of NHS spending in 2010. Nevertheless 117.1 million euros
were explained by new molecules reimbursed in the last three years. After July 2010
and due to the 1% VAT increase, the expenditure had increased 7.5 million euros.
The Health Subsystems (special security schemes for certain professions) had also
contributed positively: in December about 7.4 million euros were transferred from
the ‘ADSE’ (civil servants subsystem) for NHS. At the end of 2010, the Government
adopted further measures to control public expenditure, such as 6% prices deduc-
tion and several reductions in pharmaceuticals reimbursement levels. Immedi-
ately the NHS medicines expenditure decreased 21.2% in the four first months of
2011. In opposition the hospital market is growing 3.5%. CONCLUSIONS: Besides
price and reimbursement administrative reductions, with limited impact in the
short run, it would be important to consider measures, that should be assessed on
a periodic basis to identify the best strategies to promote rationality and efficiency
in the outpatient and hospital sector.
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OBJECTIVES: To compare the use of health care services between patients with
private and public drug insurance among users of anti-depressants. METHODS: A
matched retrospective cohort study was conducted using databases for Quebec
residents with private (reMed database) or public (RAMQ database) drug insurance.
The study included 194 reMed and 1923 RAMQ patients aged 18 to 64 years who
filled at least one prescription of an antidepressant between December 2007 and
September 2009. Patients were matched on age, sex and date of 1st filled prescrip-
tion of an antidepressant. The primary outcomes were the number of outpatients
medical visits, emergency department (ED) visit (yes/no) and hospitalization (yes/
no) for all causes over one year. The secondary outcome was the average antide-
pressant cost per patient per month. Linear or logistic regression was used to
compare the outcomes between patients with private and public drug insurance,
while adjusting for potential confounders. RESULTS: Patients with private drug
insurance (21.3% males) had 8.1 outpatient medical visits on average, 17.5% had an
ED visit and 8.8% were hospitalized over one year. Corresponding figures were 6.6,
20.0% and 8.5% for patients with public drug insurance (23.6% males). Patients with
private drug insurance were found to have more outpatient medical visits than
patients with public drug insurance (adjusted mean difference 1.2; 95%CI: 0.2 to
2.3), but were not more likely to have an ED visit (adjusted OR 0.7; 95% CI: 0.5 to 1.1)
or a hospitalization (OR0.9; 95%CI: 0.5-1.6). Average cost per patient per month for
antidepressants was $48.50 (95%CI: 44.97-52.02) and $33.73 (95%CI: 32.94-34.51) for
patients with private and public drug insurance, respectively. CONCLUSIONS: Lit-
tle differences were found in the use of health care services between users of
antidepressants with private and public drug insurance, while important differ-
ences were observed for the cost of antidepressants.
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OBJECTIVES: To explore the current status (2010) of tendering programs for outpa-
tient pharmaceuticals in the European countries and how these programs operate.
METHODS: A survey was designed to assess the features of tendering programs in
European countries. All 27 countries of the European Union plus Norway were
included in the study. The survey was sent to national representatives of authori-
ties and organizations and to academic researchers with expertise in the domain.
RESULTS: Nineteen of the 28 countries have responded to the questionnaire (68%).
Seven countries have adopted tendering programs for pharmaceuticals in ambu-
latory care. Tendering was more popular in countries with a mature generic med-
icines market (54%) than in countries with a developing generic medicines market
(12.5%). Authorities with financial interest for possible savings issued the tenders
and the lowest price/best offer was amongst the criteria to award the tender in
most cases. The frequency varied from only once to once every two weeks and the
number of winners was between one and four. The objectives of achieving cost
savings were achieved in the short term but results on long term are still unclear.
CONCLUSIONS: Tendering programs can achieve savings in the short term, but the
effects in the long term are still unclear. It can be concluded that the policy can
work, but the features of the programs such as the legal framework, the criteria to
grant the tender, the number of winners, the reward of the winner and the fre-
quency, have to be well-thought-out.
PHP68
ASSESSMENT OF THE NHS HOSPITALS’ PRODUCTIVITY IN THE REGIONAL
HEALTH AUTHORITY OF THESSALY IN GREECE
Androutsou L1, Geitona M2, Yfantopoulos J3
1Ministry of Health and Social Solidarity, Athens, Greece, 2University of Peloponnese, Athens,
Greece, 3National and Kapodistrian University of Athens, Athens, Greece
OBJECTIVES: To assess the performance in seven homogenous specialty clinics
across all NHS hospitals in the Regional Health Authority of Thessaly (RHAT), over
the period 2002-2006. METHODS: Data Envelopment Analysis by using the
Malmquist Productivity Index and its decompositions have been applied in order to
measure the technical efficiency and productivity. Clinics were considered to
transform inputs labour (medical and nursing staff) and capital (hospital beds) into
health services, approximated by the number of in-patient discharges and in-pa-
tient days, used as outputs. The model is output oriented and assumes variable
return to scale. Data were collected from hospitals’ records. RESULTS: Overall pro-
ductivity progressed in all clinics, led by technical change rather than technical
efficiency. Over the whole period the size of the clinics influences the overall effects
on hospital performance and the maximum level of outputs produced has not been
achieved using the given labour and capital inputs, except orthopaedic clinics. The
highest productivity changes were achieved by the gynecology (22.5%), the urology
(15.7%) and the paediatric clinics (15.4%). All clinics experienced high technological
change level, except general medicine clinics which drops by 6.5%. The highest
technological changes were experienced by gynecology clinics (48.4%), the paedi-
atrics (26.2%) and ophthalmology (22.1%). CONCLUSIONS: Homogeneity in assess-
ing hospitals’ performance provides evidence on the efficiency and productivity
gains among clinics and suggests improvements in those which appear inefficient.
The difficult economic situation Greece is facing nowadays makes the assessment
of NHS hospitals’ performance a priority in the decision making.
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OBJECTIVES: Muscle relaxants are used in anesthesia to obtain adequate muscle
relaxation. Our aim is obtaining improvement in hospital budget by selecting ad-
equate neuromuscular blocking agents for short-term (under 60 minutes)pediatric
operations for hospital managements. METHODS: There is a basic investigation of
the duration to recovery time of atracurium and rocuronium administrations dur-
ing anesthesia induction in ASA I-II children. In order to evaluate the effect on
hospital budget, direct expenses were used. RESULTS: The mean time to reach
TOF75 in recovery with rocuronium and atracurium were calculated 38 and 51
minutes, respectively. In atracurium group, time to reach TOF75 was 51 minutes,
but operation time was 46 minutes(as rocuronium groups)and patients needed an
additional 5 minutes for recovery. During additional minutes, patients were kept in
the operation room(OR), thus preparation for the next patient was delayed. After
extubation of patients, to determine the period of preparation of an OR for the next
patient, a questionnaire was administered. This preparation was determined to be
14 minutes. These means, in the rocuronium and atrocurium groups one needs 60
minutes (4614) and 65 minutes (5114), respectively from the start of an opera-
tion to the start of next operation. In a pediatric surgery department, lower abdom-
inal and urogenital surgery unit income with rocuronium or atracurium are the
same but, rocuronium brings extra time for an average of 15 operations lasting
shorter than 1 hour. CONCLUSIONS: Study showed that if a hospital works with
100% performance and has no other problems (shortage of bed,personnel,etc), such
a hospital may perform, in a month, an extra 15 pediatric surgical operations less
than 1 hour can, by using rocuronium. Thus rocuronium may lead an additional
income of US$ 2436 per month for one OR. In other words, in short operations, using
rocuronium rather than atracurium may lead to savings which is 30-35% of total
cost.
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OBJECTIVES: The British government has decided to impose a system of value
based pricing (VBP) in England as part of a wide-ranging national health care sys-
tem (NHS) reform. The outcomes from this decision will have a number of conse-
quences for the NHS and the pharmaceutical industry alike. The objective of this
poster is to evaluate the impact of VBP implementation on the NHS and pharma-
ceutical industry specifically with regards to drug access, health care drug expen-
diture and promoting innovation.METHODS:A literature review was conducted in
order to understand health economists’ evaluations about VBP and stakeholders’
reaction to proposed reform. Ten stakeholders from academia, the pharmaceutical
industry and representative members of the NHS, were involved in qualitative
interviews to compare and contrast the views of health care workers, NICE and the
pharmaceutical industry about NHS reform and concept of value as it pertains to
VBP. RESULTS: VBP as expected has been quite a contentious and controversial
issue for the pharmaceutical industry with regards the proposed NHS reform.
NICE’s position on value based pricing based on cost-effectiveness analyses is ar-
guably not perfect, but it does define outcomes for the pharmaceutical industry in
a more transparent manner. Clinician stakeholders, including the proposed GP
commissioning groups will have difficulty in determining value without prescribed
criteria and specified guidelines based around innovation and value. It is also ques-
tionable whether VBP would indeed spur innovation of drug development or in fact
hamper research and development due to increased market access requirements
and decreased profitability in the pharmaceutical sector. CONCLUSIONS: The def-
initions of innovation and value in the pharmaceutical industry and the NHS have
different meanings for different stakeholders. A clearer understanding of VBP and
its expected outcomes would be helpful to bridge the gap between the pharmaceu-
tical industry and the NHS.
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OBJECTIVES: Syndrome of inappropriate antidiuretic hormone hypersecretion
(SIADH) is a common cause of hyponatremia contributing to 30-50% of hyponatre-
mia cases. Little is known of the influence of SIADH on health care resource utili-
zation. This study assessed the effect of SIADH on inpatient total and intensive care
unit (ICU) cost and length of stay (LOS), the likelihood of ICU admission, and 30-,
90-, and 180-day readmission. METHODS: The Premier hospital database was uti-
lized to identify US hospital inpatients discharged between January 1, 2007 and
June 30, 2009. Hyponatremic/SIADH patients were identified using primary or sec-
ondary ICD-9 codes (n430,731) and were matched to a control group (n430,731)
using exact matching on age, gender, provider region and 3M™ APR-DRG assign-
ment. Matching was further refined using propensity scores based on additional
patient and hospital covariates. Due to the contribution of congestive heart failure
and cirrhosis on hyponatremia development, these patients were excluded from
the analysis. The final analytic sample contained 65,973 SIADH patients and
407,874 non-hyponatremia/SIADH patients. Cost was analyzed using gamma re-
gression, LOS with negative binomial regression. ICU admission and hospital read-
mission were analyzed using multivariate logistic regression. RESULTS: In contrast
to non-SIADH patients, patients with SIADH had significantly higher total inpatient
cost (55.53%,CI52.53-58.60;p.0001), ICU cost (38.07%;CI33.18-43.15;p0.0001),
total LOS (45.11%,CI43.20-47.03;p0.0001), and ICU LOS (42.72%,CI38.36-47.23;
p.0001). SIADH patients were significantly more likely to be admitted to the ICU
(OR2.131;p.0001), and readmitted at 30- (OR1.399;p0.0001), 90- (OR1.495;
p0.0001), and 180-days (OR1.459;p0.0001) in comparison with non-SIADH
patients. CONCLUSIONS: The presence of SIADH in hospitalized patients is signif-
icantly associated with increased total and ICU cost and LOS, likelihood of ICU
admission, and likelihood of readmission.
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OBJECTIVES: To describe how Thailand use evidence on country’s burden of dis-
ease and cost-effectiveness of health interventions from the 2nd edition Disease
Control Priority in Developing Countries (DCP2) to set priorities in health sector
investment in the National Health Development Plan. METHODS: The study ap-
plies comprehensive literature reviews, secondary data analyses, interview of key
informants and meeting among stakeholders to answer four specific OBJECTIVES:
a) burden of disease (BOD) priorities; b) health interventions currently imple-
mented in Thailand against what recommended by DCP2; c) costs of top-ten BOD in
terms of medical expenditure, productivity loss due to life loss and morbidity; and
d) assessment of medium term economic framework in different scenario.
RESULTS: Since 1999 there has been an increasing trend in BOD attributable from
alcohol and tobacco consumption, consumption of high fat high calorie diet, lack of
fibre food and physical activities, increasing incidence of diabetes mellitus, hyper-
tension and high blood lipid, traffic injuries, overweight and obesity. Evidence from
the share of DALY loss, productivity loss and absenteeism from morbidity indicates
three national health priorities: HIV/AIDS; traffic injuries and diabetes mellitus.
Total health expenditure in 2009 was 179 USD per capita, 4.3% of GDP, and mostly
spent on curative services, only 4.5% of that was for disease prevention and health
promotion. CONCLUSIONS: Thailand can invest more on health of the population,
in particular on disease prevention and health promotion to address three national
health priorities: HIV/AIDS, traffic injuries and diabetes mellitus through cost effective
interventions in and outside the health sector. The most probable scenario for increas-
ing investment in health promotion and disease prevention is to double the amount of
investment for health promotion and disease prevention. Also, resources can be mo-
bilized from local administrations and communities, and should be managed by effi-
cient and accountable agency with effective mechanisms.
PHP73
GOVERNMENT REDUCES PUBLIC PHARMACEUTICAL EXPENDITURE IN
HUNGARY: RATIONAL DECISIONS IN CHALLENGING ECONOMIC TIMES?
Inotai A1, Merész G1, Kalo Z2
1Syreon Research Institute, Budapest, Hungary, 2Eötvös Loránd University, Budapest, Hungary
OBJECTIVES: Scarcity of public resources, especially in challenging economic
times, draws attention to the expenditure on pharmaceuticals. Over the next 3
years the Hungarian government plans to reduce the public pharmaceutical spend-
ing by 35%. Our objective was to assess the current level of pharmaceutical expen-
diture in Hungary by taking into account the economic status of the country and
benchmarks from other OECD countries with special focus on Visegrad countries
(Czech Republic, Slovakia, Poland, Hungary). METHODS: We completed interna-
tional cross sectional and cluster analysis based on OECD Health Data 2010 and
longitudinal analysis of public pharmaceutical expenditure in Hungary. RESULTS:
The cluster analysis indicates that pharmaceutical spending is relatively higher in
middle-income countries compared to high income countries above 30’000 USD
GDP/capita (1.89 vs. 1.41% of GDP%, p0.04; 23.58% vs. 14.14% of total health ex-
penditure, p0.001), as prices of pharmaceuticals are not adjusted to local price
levels as opposed to prices of other health care services. International trends of the
global pharmaceutical market are also valid in Hungary. The public pharmaceuti-
cal spending is close to the average of Visegrad countries, but the private pharma-
ceutical spending is the highest. The annual real growth rate of public pharmaceu-
tical spending was only 1.0% between 1994-2010, whilst increased private funding
(mainly out of pocket payments) was the major growth driver of total pharmaceu-
tical expenditure in Hungary.CONCLUSIONS:Cost-containment of public pharma-
ceutical spending was very successful in the last 15 years. The burden of pharma-
ceutical market growth has been shifted to private households. The proposed
public budget cut translates to over 30% decrease in real public pharmaceutical
spending from 1994 to 2014. As morbidity and mortality indicators of the Hungar-
ian population are extremely unfavourable, current evidences and international
benchmarks do not justify significant reduction of the public pharmaceutical bud-
get.
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Greek law (3816/2010) sets a list for serious diseases products (89 in total) which can
be dispensed either through public hospitals or retail pharmacies for non hospital-
ized patients. Each distribution channel incurs different costs for the NHS (public
hospitals/SSFs). OBJECTIVES: Estimate potential savings for GR NHS (Social Secu-
rity Funds & Hospitals) through dispensing products of serious diseases through
hospital pharmacies instead of retail pharmacies. METHODS: Data derived from
drug reimbursement database of OGA (Agriculture SSF) covering 20% of the GR
population. The data represent actual reimbursement amounts to private pharma-
cies, from January to April 2011, extrapolated for the whole 2011. The price calcu-
lations were based on the following formulas: 1) Public hospitals buy at hospital
price (HP)VAT from pharmaceutical companies; 2) Public hospitals charge whole-
saler price3% premium to SSFs; and 3) Retail pharmacies charge SSFs retail price
(calculated as hospital price 2,5%wholesaler margin 18% pharmacy margin
VAT). RESULTS: Based on the mean of 5950 prescriptions per month the average
value paid by OGA to the retail pharmacies was €1042 per prescription. By changing
dispensing channel, via hospital, the mean cost per prescription for OGA was esti-
mated at €930.93. Since both SSFs & hospitals are part of NHS, the actual cost of
NHS/prescription is the hospital cost estimated at €818.72 and the estimated hos-
pital gain per prescription is €112.21. The actual gain for NHS per prescription is
€223.28. The extrapolated gain for OGA for 2011 is estimated at €7,930.398 while for
NHS is €15,942.192. CONCLUSIONS: Distribution of products for serious diseases
via hospital pharmacies, leads to considerable savings for NHS and SSFs while
ensuring considerable gains for hospitals, under specific conditions (hospital per-
sonnel, budget, immediate payment by SSF). The expansion of the list is of absolute
priority for reducing the NHS spending. More savings can be achieved by dispens-
ing L3816 products through the newly formed unified health care fund (EOPYY)
covering 90% of total population.
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